The application for the renewal of the approval of the active substance fludioxonil was submitted on 26 October 2015 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 29 March 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 21 February 2018, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 13 January and 14 March 2023. On 2 May 2019, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 6 June 2019 within the deadline given. On 4 July 2019, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 20 December 2021 within the deadline given. On 25 September 2024, the Authority adopted its conclusion and communicated it to the applicant, the Member States and the Commission. The Commission initiated preliminary discussions on the renewal of the approval of the active substance fludioxonil in the Standing Committee on Plants, Animals, Food and Feed on 4 December 2024. The Commission is preparing a draft implementing regulation and a draft review report on the renewal of the approval of this active substance, to be submitted to the Standing Committee. As additional time is necessary for the delivery of the opinion of that Committee and for the Commission to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 12 months, until 30 September 2027.
Recital 30, Regulation (EU) 2026/1826
In forcesince 28 Jul 2026